Affiliation:
1. Dept. of Rheumatology, Karolinska University Hospital, Solna, 171 76 Stockholm, Sweden.
Abstract
Rheumatoid arthritis is a chronic inflammatory systemic autoimmune disorder characterized by symmetric inflammation of synovial joints, leading to progressive erosion of cartilage and bone. Tumor necrosis factor-α antagonists have set a new therapeutic standard for rheumatoid arthritis. Tumor necrosis factor-α blocking agents, including infliximab, etanercept and adalimumab, have demonstrated substantial improvement in signs and symptoms, disability and quality of life, while significantly inhibiting joint damage in early and long-standing rheumatoid arthritis. The focus of this article will be the role of infliximab in the treatment of rheumatoid arthritis.
Subject
Geriatrics and Gerontology,General Medicine
Reference92 articles.
1. FiresteinGS: Etiology and pathogenesis of rheumatoid arthritis. In:Kelley's Textbook of Rheumatology (Volume 2, 7th Edition).Harris ED (Ed). Elsevier Science, USA,996–1042 (2005).
2. DEVELOPMENT OF RADIOGRAPHIC DAMAGE DURING THE FIRST 5–6 YR OF RHEUMATOID ARTHRITIS. A PROSPECTIVE FOLLOW-UP STUDY OF A SWEDISH COHORT
3. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis.
4. HarrisED: Clinical features of rheumatoid arthritis. In:Kelley's Textbook of Rheumatology (Volume 2, 7th Edition).Harris ED (Ed.) Elsevier Science, USA,1043–1078 (2005).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献